Drug Trial News

RSS

Moderna vaccine reduced viral load and protected against SARS-CoV-2 variants in new phase 3 trial

Coronavirus research has shown that higher viral loads are associated with severe COVID-19 infection. But new results from the phase III Coronavirus Efficacy (COVE) clinical trial find the Moderna vaccine reduces severe acute respiratory coronavirus 2 (SARS-CoV-2) viral load and viral shedding.

30 Sep 2021

How effective are COVID-19 vaccines against SARS-CoV-2 variants of concern?

The authors from this paper performed a systematic review and meta-analysis evaluating vaccine effectiveness from RCTs and observational studies.

29 Sep 2021

Clinical study tests novel topical corneal epithelial stem cell-derived product for treating dry eye disease

Several studies conducted over the last decade have concluded that dry eye disease (DED) affects up to 50% of the U.S. population, creating a liability for the nation's health care system that is estimated to exceed $50 billion annually.

28 Sep 2021

Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that SAB-185, a novel polyclonal antibody therapy, has demonstrated safety and efficacy in phase 2 that meet the criteria for graduation to phase 3 in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401).

28 Sep 2021

Trial of Sanofi/GSK SARS-CoV-2 vaccine boosters against variants in non-human primates

New research discusses the development of soluble prefusion-stabilized spike trimers (CoV2 preS dTM) comprising adjuvant AS03.

27 Sep 2021

B cell activating anti-CD73 antibody for the immunotherapy of COVID-19

Despite the advent of numerous vaccines and the discovery of passive monoclonal antibodies for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), there remains an urgent need for definitive therapies for coronavirus disease-2019 (COVID-19) patients.

27 Sep 2021

Promising data from early clinical trials of new anticancer therapies presented at ESMO Congress 2021

Data from early clinical trials presented at the ESMO Congress 2021 suggest that new anticancer treatments are on the horizon, with a clear emphasis on precision medicine.

24 Sep 2021

Research reveals underperformance of many Phase III oncology trials

New research in the September 2021 issue of JNCCN-;Journal of the National Comprehensive Cancer Network finds that more than 80% of therapies tested in Phase III oncology trials did not achieve meaningful clinical benefit in prolonging survival.

24 Sep 2021

Novel anti-hormonal therapy may be a new treatment option for early-stage breast cancer

Early results from a UCLA-led clinical trial found treating women with estrogen receptor (ER)-positive and human epidermal growth factor receptor-2 (HER2)-negative early breast cancers with a novel type of anti-hormonal therapy, called an oral selective estrogen receptor degrader (SERD), led to clinically meaningful reductions in tumor activity prior to surgery.

21 Sep 2021

Sunitinib extends progression-free survival in patients with rare neuroendocrine tumor, study shows

The first randomized study in malignant pheochromocytoma and paraganglioma (MPP) has found that sunitinib prolongs progression-free survival (PFS) by more than five months.

20 Sep 2021

Failures and findings from randomized clinical trials in COVID-19 convalescent plasma

Researchers complete an extensive search on previously published studies to understand the efficacy of convalescent plasma in treating COVID-19.

20 Sep 2021

Immunotherapy treatment may be appropriate for patients with earlier stages of melanoma

An immunotherapy called pembrolizumab reduced cancer recurrence after surgery in patients with stage IIb and IIc melanoma, according to the results of an international, randomized phase III clinical trial led by UPMC Hillman Cancer Center.

20 Sep 2021

A new synthetic multiantigen MVA vaccine COH04S1 effective against SARS-CoV-2

A new study utilized MVA to develop vaccine candidates that were subsequently evaluated in animal models of congenital cytomegalovirus disease.

19 Sep 2021

New data shows benefit of drug combination for metastatic castration resistant prostate cancer

New findings by researchers at Yale Cancer Center show the drug combination of nivolumab and rucaparib shows clinical activity for patients with chemotherapy-naïve, metastatic castration resistant prostate cancer (mCRPC).

18 Sep 2021

Novel drug combinations improve progression-free survival for patients with advanced NSCLC

New findings from a large study led by researchers at Yale Cancer Center shows the addition of the drugs oleclumab or monalizumab to durvalumab improved progression-free survival for patients with locally advanced non-small cell lung cancer (NSCLC).

18 Sep 2021

UW Medicine enrolls volunteers for COVID-19 booster vaccine trial

Researchers at the University of Washington School of Medicine are enrolling volunteers for a COVID-19 booster vaccine trial.

18 Sep 2021

Temple research paves the way for first Phase 1/2 clinical trials of CRISPR-based therapy for HIV

For the last seven years, researchers at the Lewis Katz School of Medicine at Temple University have been developing and refining CRISPR-based gene-editing technology for the treatment of human immunodeficiency virus type 1 (HIV) infection.

17 Sep 2021

Single dose of typhoid conjugate vaccine found to be safe and effective in Malawian kids

A new study, published today in the New England Journal of Medicine, finds a single dose of typhoid conjugate vaccine (TCV) – the only typhoid vaccine licensed for children as young as 6 months – is safe and 84 percent effective in protecting against typhoid in Blantyre, Malawi.

16 Sep 2021

Phase I trial investigates using antiparasitic nitazoxanide for treatment of COVID-19

In a recent study, researchers investigate the possibility of using the thiazolide antiparasitic nitazoxanide for the treatment of COVID-19.

15 Sep 2021

A review of mesenchymal stem cell therapy for severe COVID-19

Researchers find that MSC treatment is highly tolerated and effective in reducing lung damage in COVID-19 patients and improving their chances of recovery.

13 Sep 2021

Previous
1
...
43
44
45
46
47
48
49
...
1143
Next

Drug Trial News

Moderna vaccine reduced viral load and protected against SARS-CoV-2 variants in new phase 3 trial

How effective are COVID-19 vaccines against SARS-CoV-2 variants of concern?

Clinical study tests novel topical corneal epithelial stem cell-derived product for treating dry eye disease

Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial

Trial of Sanofi/GSK SARS-CoV-2 vaccine boosters against variants in non-human primates

B cell activating anti-CD73 antibody for the immunotherapy of COVID-19

Promising data from early clinical trials of new anticancer therapies presented at ESMO Congress 2021

Research reveals underperformance of many Phase III oncology trials

Novel anti-hormonal therapy may be a new treatment option for early-stage breast cancer

Sunitinib extends progression-free survival in patients with rare neuroendocrine tumor, study shows

Failures and findings from randomized clinical trials in COVID-19 convalescent plasma

Immunotherapy treatment may be appropriate for patients with earlier stages of melanoma

A new synthetic multiantigen MVA vaccine COH04S1 effective against SARS-CoV-2

New data shows benefit of drug combination for metastatic castration resistant prostate cancer

Novel drug combinations improve progression-free survival for patients with advanced NSCLC

UW Medicine enrolls volunteers for COVID-19 booster vaccine trial

Temple research paves the way for first Phase 1/2 clinical trials of CRISPR-based therapy for HIV

Single dose of typhoid conjugate vaccine found to be safe and effective in Malawian kids

Phase I trial investigates using antiparasitic nitazoxanide for treatment of COVID-19

A review of mesenchymal stem cell therapy for severe COVID-19

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News